Engineering Antibodies banner

第8回年次会議「抗体工学」

「抗体工学」プログラムでは、現在の課題を克服するために、クラス最高の抗体や治療用タンパク質を設計するための探求を続けています。この会議では、高アビディティ、良好なターゲティング、多重特異性、多価性、免疫刺激、または条件付き活性化の目標を達成するために、新しい分子や新興フォーマットの設計とエンジニアリングのための斬新なプラットフォームについて、バイオファーマのベテランや新進気鋭のバイオベンチャーからお話を伺います。ぜひご参加ください。

11月15日(水)

Registration Open and Morning Coffee07:30

NOVEL PLATFORMS
新規プラットフォーム

08:25

Chairperson's Opening Remarks

Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare AG

08:30 KEYNOTE PRESENTATION:

Discovery of Antibody-Based Therapeutics to Challenging Targets: Platform Considerations

Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen, Canada

Discovery of large molecule-based therapeutics to complex targets requires diverse approaches. Previously, we took advantage of an internally developed enhanced hybridoma platform, which enabled deep interrogation of in vivo derived immune repertoires. Today, we have transitioned to B cell discovery platforms, which enable accessing differential compartments in the immunized animal. We supplement our capabilities with mammalian display to solve immunologically intractable targets. The decision on which platform to utilize is dictated by anticipated target difficulty and program design goals. The combination of high-precision B cell technologies coupled with display and NGS sequencing form the foundation of our discovery engine.

09:00

Biology-Based Engineering of Versatile Antibody and Albumin Technologies

Jan Terje Andersen, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital

The long plasma half-life of IgG and albumin is regulated by a broadly expressed receptor, FcRn. As such, insights into how FcRn is transporting its ligands within and across cellular layers have implications for design of modalities that directly or indirectly engage the receptor. I will discuss how this complex biology can be explored in engineering of albumin and antibody formats that enhance or restrict transport across cellular barriers.

09:30 Talk Title to be Announced

Speaker to be Announced

Session Break to Transition into Plenary Keynote10:00

PLENARY KEYNOTE SESSION
基調講演(プレナリーセッション)

10:10

Introduction

Enkelejda Miho, PhD, Professor, Dean, University of Applied Sciences and Arts Northwestern Switzerland

10:15

Benchmarking the Impact of AI Biologics Discovery and Optimisation for Pharma

Rebecca Croasdale-Wood, PhD, Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca

The biologics landscape is rapidly changing with the number of AI-enabled biologics in pre-clinical and clinical stages estimated to be 50-60 (1). This change is driven by the increase in enterprise software solutions to capture and store data, augmented discovery workflows, improvements in machine learning technology, and advances in computing power. Augmented biologics discovery has the potential to revolutionize biologics discovery, yet information of how in silico technologies perform, versus traditional discovery platforms is scarce. At PEGS Europe, we will present current in silico biologics design and optimisation technologies, with a focus on our internal efforts to benchmark the impact of combining novel in silico technologies with our existing biologics discovery platforms.

Coffee Break in the Exhibit Hall with Poster Viewing11:00

BISPECIFIC AND MULTI-SPECIFIC ANTIBODIES
二重特異性、多重特異性抗体

11:45

UniStac: Enzyme-Mediated Conjugation Technology for Accelerated Development of Tetraspecific NASH Drug

Sungjin Park, PhD, CEO, Onegene Biotechnology

UniStac, novel enzyme-mediated protein-protein conjugation technology, expedites multi-target drug development by simply conjugating two proteins into a single Y-shaped, antibody-like molecule, eliminating the need for Fc heteromerization optimization. The large-scale production success of OGB21502, a leading tetra-specific NASH drug, at 99.5% conjugation yield, highlights its commercial feasibility. In preclinical animal studies, OGB21502 demonstrated improved efficacy in addressing NASH, insulin sensitivity, glucose regulation, and fibrosis resolution compared to single-mechanism treatments that are in clinical stage. UniStac's accelerated development enables efficient exploration of tri- and tetra-specific combinations, unencumbered by manufacturing constraints and modality choices.

12:15

Programmable DNA-Origami-Based T Cell Engagers: PTE

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic

We developed modular and programmable assemblies of IgG antibodies, Fab fragments, and scFv on DNA-origami nanocarriers to create stable multi-specific antibody-DNA hybrids. These hybrids bind readily to cells, have favorable pharmacokinetic properties, and efficiently activate T cells in the presence of effector cells. The plattform allowed us to identify T cell engagers that showed specific and efficient T cell-mediated lysis of target cells in vitro and in vivo. Our approach enables rapid generation, screening, and testing of next-generation multi-specific immune cell engaging antibodies for pharmaceutical development.

12:45 Anti-GARP/TGFb1 Antibodies in a New Twist - Multifunctional Shapers of Anti-Tumor Immunity

Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics

High GARP/TGFβ-1 surface expression on both Tregs and cancer cells results in LTGFβ-1 activation and TGFβ-1-induced immunosuppression in the tumor microenvironment. This correlates with poor prognosis and treatment failures in several human cancers. Pure Biologics developed fully human anti-GARP/TGFβ-1 IgGs and bispecifics with enhanced ADCC properties. These molecules demonstrate a multi-modal tumour killing by overcoming TGFβ-1-induced immunosuppression. This talk explores the discovery and development work performed with support from evitria AG.

Session Break13:15

13:20 LUNCHEON PRESENTATION:Talk Title to be Announced

Speaker to be Announced

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own13:50

Session Break14:20

ENGINEERING FOR HIGHER AVIDITY AND MULTI-VALENCY
高アビディティ、多価性に対するエンジニアリング

14:30

Chairperson's Remarks

Bruce Keyt, PhD, CSO, R&D, IGM Biosciences, Inc.

14:35

IgM Antibodies as Receptor Cross-Linking Agents for DR-5 and Other TNF Targets

Bruce Keyt, PhD, CSO, R&D, IGM Biosciences, Inc.

Engineered IgMs have high affinity, strong avidity and robust receptor cross-linking capability. IgM agonists trimerize TNF receptors exhibiting more than 1000x increased apoptotic activity compared to corresponding IgGs. IgMs are highly structured and with appropriate epitope selection, antibodies can be developed with best-in-class safety, with wide therapeutic index. This talk will provide updates on research and clinical status of IGM-8444 (anti-DR5 IgM) for treatment of colorectal carcinoma.

15:05

Avidity Engineering: A Next Frontier in the Development of Differentiating Antibody Therapeutics

Simone Oostindie, PhD, Director, Research and Discovery, Gyes B.V.

This presentation explores the concept of antibody avidity engineering, which involves optimizing multivalent interactions of antibodies with their targets to unlock novel functionalities and mechanisms-of-action, offering new opportunities for developing differentiated antibody therapeutics with enhanced selectivity and potency.

15:35 Accelerating Functional TCR Discovery by Phenotyping Thousands of Live, Single T Cells in Two Days

Troy Lionberger, PhD, Senior Vice President, Business Development, PhenomeX

This presentation will introduce a high-throughput screening technology platform capable of observing single T cells in co-culture with antigen-presenting cells (APCs). During the time-course observation, >1,000 single T cells are monitored for their ability to kill APCs in co-culture, surface marker expression, and cytokine secretion. Recovering functional T cells from patient samples using this two-day workflow can accelerate therapeutic TCR discovery, T cell vaccine development, and patient immune monitoring.

Refreshment Break in the Exhibit Hall with Poster Viewing16:05

ENGINEERING FOR PRECISION TARGETING, AFFINITY, AND DEVELOPABILITY
精密ターゲティング、アフィニティ、開発可能性に対するエンジニアリング

17:00

Molecule Formats for Tumour Targeting of Radiotherapies

Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare AG

Successful tumor treatment with Targeted Radio Therapies (TRTs) relies on the selection of the most appropriate combination of high-energy radio emitter, chelator, and linker, as well as tumor targeting moiety. Although TRTs share similarities with ADCs, their unique mode of action requires different strategies.

17:30

Engineering Hyperstable Synthetic Miniproteins as Developable Ligands

Benjamin J. Hackel, PhD, Professor, Chemical Engineering & Materials Science, University of Minnesota

Synthetic miniproteins are compelling scaffolds for binding ligands with advantageous modularity, physiological transport, and efficient synthesis. We have evaluated the developability and evolvability of >50 miniprotein libraries systematically varied across topology, framework, and paratope location. We evolved binders to eight targets and measured proxies of solubility, expression, and stability for millions of scaffold variants. The results elucidate biophysical factors that dictate miniprotein scaffold performance thereby empowering library and clone design.

18:00

Engineering Bicyclic Peptides for Precision Targeted Medicine

James Cooke, PhD, Associate Director, Bicycle Therapeutics

The Bicycle platform uses proprietary bicyclic peptide phage display technology to deliver a unique toolkit of building blocks to create novel medicines. Bicycles combine rapid extravasation and extensive tissue penetration with renal clearance and tuneable half-life. This talk describes how Bicycles targeted to tumour antigens are engineered, seeking to deliver cytotoxic or radionuclide payloads, or combined with immune agonist Bicycles to seek to deliver tumour killing as precision targeted medicines.

18:30

Learning Antibody Binding Affinity Using FACS and NGS

Iain H. Moal, PhD, Scientific Leader, Computational Antibody Engineering, GSK

An ML model was generated to accelerate the antibody selection from our yeast display platform by reducing the number of FACS/NGS rounds. The built model predicts the progression between rounds and therefore which mutations and combinations influence affinity.

Close of Engineering Antibodies Conference19:00


* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
English



Premier Sponsors

Asimov Inc

Evitria

Immatics-Biotechnologies

Integral-Molecular_NEW

LONZA

Phenomex Logo